Venture capital

How AI is forcing VCs to rethink their timelines

[SINGAPORE] There’s a lot of talk about how much generative AI has changed the startup game, but what’s less discussed is the extent of the sector’s impact on venture capital itself.

In the past three decades, Singaporean venture capitalist Jenny Lee has proven her mettle with her trailblazing spirit.

How Jenny Lee became Asia’s ‘Iron Woman’ of venture capital

She is also a frequent presence in global top 100 most influential women lists

(From left) HSBC's senior leaders Jonathan Yip, Gilbert Ng, David Sabow and Neil Falconer at the launch of HSBC Innovation Banking with the bank's clients. The lender will set aside US$1.5 billion to support this new banking segment.

HSBC brings startup-focused Innovation Banking to Singapore, allocates US$1.5 billion to finance high-growth companies

Lender will execute a go-to-market strategy that covers both entrepreneurs and venture capital firms

Compared with other industries, biotech startups typically have long and uncertain timelines, as well as high capital requirements – all of which translate into perceived higher risk.

Challenging economic conditions raise the bar for nascent biotech startups as funding dries up

The pullback in science and tech funding in the US has cooled investor sentiment for now, but observers say more money may eventually flow into Asia and Europe

The impact of Trump’s pharma tariffs on drugmakers is evident, but the upstream implications for startups developing novel drugs are less clear.

Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off

Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term outlook is unlikely to change

Nvidia CEO Jensen Huang is among several high-profile Silicon Valley executives who accompanied US President Donald Trump on a state visit to the UK this week.

Nvidia to invest in UK firms including Wayve, Revolut

The chipmaker’s financing is one of a slew of AI announcements from US technology companies this week, coinciding with Trump’s visit

China has accounted for over 75% of regional venture capital and private equity funding since 2019, and now contributes 26.7% of all drugs in the global development pipeline – up from 23.6% the year before, says Bain & Company.

China’s biotech boom: Collaboration, not competition, for Singapore

While China dominates global drug development, Singapore’s strength lies in bridging Asian innovation with Western capital, say industry players

The top early-stage investor in the South-east Asian tech ecosystem for the period was Seeds Capital – the investment arm of Enterprise Singapore – followed by Integra Partners and Tin Men.

Singapore tech firms bag majority of S-E Asia funding for 9M 2025, at US$2.3 billion: report 

But overall funding levels in South-east Asia have contracted year on year; the Philippines is a ‘bright spot’ in the region

Robotics, AI and cloud are some of the sectors in China that still draw investments from venture capitalists, market players say.
HOCK LOCK SIEW

Will China’s venture capital market become investable again?

Deal value slumps 36% year on year in first eight months of 2025 as investors shy away from trade tensions, domestic challenges

China manufactures about 80% of the world’s solar panels.

China road trip exposes list of uninvestable assets in the West

Global clean-tech dominance has not necessarily meant profits for Chinese firms